SPRC
HEALTHCARESciSparc Ltd
$6.38-0.53 (-7.67%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SPRC Today?
No stock-specific AI insight has been generated for SPRC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.98$80.10
$6.38
Fundamentals
Market Cap$4M
P/E Ratio0.1
EPS$98.07
Dividend Yield—
Dividend / Share—
ROE-12.8%
Profit Margin—
Debt / Equity—
Trading
Volume31K
Avg Volume (10D)—
Shares Outstanding573K
SPRC News
20 articles- SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression TherapyYahoo Finance·Mar 16, 2026
- NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression TherapyYahoo Finance·Mar 16, 2026
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression TherapyYahoo Finance·Mar 13, 2026
- SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseYahoo Finance·Mar 12, 2026
- NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseYahoo Finance·Mar 11, 2026
- SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trailsYahoo Finance·Mar 10, 2026
- Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseYahoo Finance·Mar 10, 2026
- Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd.Yahoo Finance·Mar 10, 2026
- SciSparc announces 1-for-9 reverse share splitYahoo Finance·Mar 3, 2026
- SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSAYahoo Finance·Feb 2, 2026
- Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance Such as MRSAYahoo Finance·Feb 2, 2026
- SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate CommercializationYahoo Finance·Jan 26, 2026
- SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar OpportunityYahoo Finance·Jan 13, 2026
- SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-ComplianceYahoo Finance·Jan 12, 2026
- SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side EffectsYahoo Finance·Dec 30, 2025
- Neurothera Labs Granted Patent by Israeli Patent Office for Its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side EffectsYahoo Finance·Dec 30, 2025
- IM Cannabis Appoints Asi Levi as Chief Financial OfficerYahoo Finance·Dec 12, 2025
- Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis CompanyYahoo Finance·Dec 2, 2025
- SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis CompanyYahoo Finance·Dec 2, 2025
- SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP PortfolioYahoo Finance·Dec 1, 2025
All 20 articles loaded
Price Data
Open$7.00
Previous Close$6.91
Day High$7.19
Day Low$6.17
52 Week High$80.10
52 Week Low$2.98
52-Week Range
$2.98$80.10
$6.38
Fundamentals
Market Cap$4M
P/E Ratio0.1
EPS$98.07
Dividend Yield—
Dividend / Share—
ROE-12.8%
Profit Margin—
Debt / Equity—
Trading
Volume31K
Avg Volume (10D)—
Shares Outstanding573K
About SciSparc Ltd
SciSparc Ltd., a specialized clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company is headquartered in Tel Aviv, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—